Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM.

McKinney A, Lindberg OR, Engler JR, Chen KY, Kumar A, Gong H, Lu KV, Simonds EF, Cloughesy TF, Liau LM, Prados M, Bollen AW, Berger MS, Shieh JTC, James CD, Nicolaides TP, Yong WH, Lai A, Hegi ME, Weiss WA, Phillips JJ.

Mol Cancer Ther. 2019 Sep;18(9):1565-1576. doi: 10.1158/1535-7163.MCT-18-1330. Epub 2019 Jul 3.

PMID:
31270152
2.

The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.

Saleem H, Kulsoom Abdul U, Küçükosmanoglu A, Houweling M, Cornelissen FMG, Heiland DH, Hegi ME, Kouwenhoven MCM, Bailey D, Würdinger T, Westerman BA.

Drug Resist Updat. 2019 Mar;43:29-37. doi: 10.1016/j.drup.2019.04.002. Epub 2019 Apr 22.

3.

Improving survival in molecularly selected glioblastoma.

Stupp R, Lukas RV, Hegi ME.

Lancet. 2019 Feb 16;393(10172):615-617. doi: 10.1016/S0140-6736(18)33211-2. Epub 2019 Feb 14. No abstract available.

PMID:
30782332
4.

MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.

Hegi ME, Genbrugge E, Gorlia T, Stupp R, Gilbert MR, Chinot OL, Nabors LB, Jones G, Van Criekinge W, Straub J, Weller M.

Clin Cancer Res. 2019 Mar 15;25(6):1809-1816. doi: 10.1158/1078-0432.CCR-18-3181. Epub 2018 Dec 4.

PMID:
30514777
5.

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.

Mansouri A, Hachem LD, Mansouri S, Nassiri F, Laperriere NJ, Xia D, Lindeman NI, Wen PY, Chakravarti A, Mehta MP, Hegi ME, Stupp R, Aldape KD, Zadeh G.

Neuro Oncol. 2019 Feb 14;21(2):167-178. doi: 10.1093/neuonc/noy132.

PMID:
30189035
6.

Toward methylation-based classification of central nervous system tumors.

Hegi ME, Kleihues P, Wen PY, Suvà ML.

Neuro Oncol. 2018 Apr 9;20(5):579-581. doi: 10.1093/neuonc/noy023. No abstract available.

7.

Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.

Gao Y, Weenink B, van den Bent MJ, Erdem-Eraslan L, Kros JM, Sillevis Smitt P, Hoang-Xuan K, Brandes AA, Vos M, Dhermain F, Enting R, Ryan GF, Chinot O, Ben Hassel M, van Linde ME, Mason WP, Gijtenbeek JMM, Balana C, von Deimling A, Gorlia T, Stupp R, Hegi ME, Baumert BG, French PJ.

Eur J Cancer. 2018 May;94:168-178. doi: 10.1016/j.ejca.2018.02.023. Epub 2018 Mar 20.

PMID:
29571083
8.

In vivo characterization of brain metabolism by 1 H MRS, 13 C MRS and 18 FDG PET reveals significant glucose oxidation of invasively growing glioma cells.

Lai M, Vassallo I, Lanz B, Poitry-Yamate C, Hamou MF, Cudalbu C, Gruetter R, Hegi ME.

Int J Cancer. 2018 Jul 1;143(1):127-138. doi: 10.1002/ijc.31299. Epub 2018 Feb 21.

9.

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.

Bady P, Kurscheid S, Delorenzi M, Gorlia T, van den Bent MJ, Hoang-Xuan K, Vauléon É, Gijtenbeek A, Enting R, Thiessen B, Chinot O, Dhermain F, Brandes AA, Reijneveld JC, Marosi C, Taphoorn MJB, Wick W, von Deimling A, French P, Stupp R, Baumert BG, Hegi ME.

Acta Neuropathol. 2018 Apr;135(4):601-615. doi: 10.1007/s00401-018-1810-6. Epub 2018 Jan 24.

10.

Ubiquitin Specific Peptidase 15 (USP15) suppresses glioblastoma cell growth via stabilization of HECTD1 E3 ligase attenuating WNT pathway activity.

Oikonomaki M, Bady P, Hegi ME.

Oncotarget. 2017 Nov 30;8(66):110490-110502. doi: 10.18632/oncotarget.22798. eCollection 2017 Dec 15.

11.

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.

Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z.

JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718. Erratum in: JAMA. 2018 May 1;319(17):1824.

12.

Glioma epigenetics: From subclassification to novel treatment options.

Gusyatiner O, Hegi ME.

Semin Cancer Biol. 2018 Aug;51:50-58. doi: 10.1016/j.semcancer.2017.11.010. Epub 2017 Nov 21. Review.

PMID:
29170066
13.

Correlation of immune phenotype with IDH mutation in diffuse glioma.

Berghoff AS, Kiesel B, Widhalm G, Wilhelm D, Rajky O, Kurscheid S, Kresl P, Wöhrer A, Marosi C, Hegi ME, Preusser M.

Neuro Oncol. 2017 Oct 19;19(11):1460-1468. doi: 10.1093/neuonc/nox054.

14.

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.

Blumenthal DT, Gorlia T, Gilbert MR, Kim MM, Burt Nabors L, Mason WP, Hegi ME, Zhang P, Golfinopoulos V, Perry JR, Hyun Nam D, Erridge SC, Corn BW, Mirimanoff RO, Brown PD, Baumert BG, Mehta MP, van den Bent MJ, Reardon DA, Weller M, Stupp R.

Neuro Oncol. 2017 Aug 1;19(8):1119-1126. doi: 10.1093/neuonc/nox025.

15.

Current management of low-grade gliomas.

Hottinger AF, Hegi ME, Baumert BG.

Curr Opin Neurol. 2016 Dec;29(6):782-788. Review.

PMID:
27676279
16.

Early detection of human glioma sphere xenografts in mouse brain using diffusion MRI at 14.1 T.

Porcari P, Hegi ME, Lei H, Hamou MF, Vassallo I, Capuani S, Gruetter R, Mlynarik V.

NMR Biomed. 2016 Nov;29(11):1577-1589. doi: 10.1002/nbm.3610. Epub 2016 Sep 15.

17.

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJB, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JMM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe D, Mason WP, Stupp R.

Lancet Oncol. 2016 Nov;17(11):1521-1532. doi: 10.1016/S1470-2045(16)30313-8. Epub 2016 Sep 27.

18.

Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).

Wick W, Gorlia T, Bady P, Platten M, van den Bent MJ, Taphoorn MJ, Steuve J, Brandes AA, Hamou MF, Wick A, Kosch M, Weller M, Stupp R, Roth P, Golfinopoulos V, Frenel JS, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte B, Pesce G, Hegi ME.

Clin Cancer Res. 2016 Oct 1;22(19):4797-4806. Epub 2016 May 3.

19.

Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors.

Bady P, Delorenzi M, Hegi ME.

J Mol Diagn. 2016 May;18(3):350-361. doi: 10.1016/j.jmoldx.2015.11.009. Epub 2016 Feb 27.

20.

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.

Weller M, Nabors LB, Gorlia T, Leske H, Rushing E, Bady P, Hicking C, Perry J, Hong YK, Roth P, Wick W, Goodman SL, Hegi ME, Picard M, Moch H, Straub J, Stupp R.

Oncotarget. 2016 Mar 22;7(12):15018-32. doi: 10.18632/oncotarget.7588.

21.

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.

Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z.

JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669.

22.

Genome-wide DNA methylation detection by MethylCap-seq and Infinium HumanMethylation450 BeadChips: an independent large-scale comparison.

De Meyer T, Bady P, Trooskens G, Kurscheid S, Bloch J, Kros JM, Hainfellner JA, Stupp R, Delorenzi M, Hegi ME, Van Criekinge W.

Sci Rep. 2015 Oct 20;5:15375. doi: 10.1038/srep15375.

23.

Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?

Hegi ME, Stupp R.

Neuro Oncol. 2015 Nov;17(11):1425-7. doi: 10.1093/neuonc/nov198. Epub 2015 Sep 15. No abstract available.

24.

WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1.

Vassallo I, Zinn P, Lai M, Rajakannu P, Hamou MF, Hegi ME.

Oncogene. 2016 Jan 7;35(1):12-21. doi: 10.1038/onc.2015.61. Epub 2015 Mar 16.

25.

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.

Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH, Mazurkiewicz M, Salacz M, Ashby L, Zagonel V, Depenni R, Perry JR, Hicking C, Picard M, Hegi ME, Lhermitte B, Reardon DA.

Neuro Oncol. 2015 May;17(5):708-17. doi: 10.1093/neuonc/nou356. Epub 2015 Mar 11.

26.

Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma.

Kurscheid S, Bady P, Sciuscio D, Samarzija I, Shay T, Vassallo I, Criekinge WV, Daniel RT, van den Bent MJ, Marosi C, Weller M, Mason WP, Domany E, Stupp R, Delorenzi M, Hegi ME.

Genome Biol. 2015 Jan 27;16:16. doi: 10.1186/s13059-015-0583-7.

27.

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.

Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wöhrer A, Dieckmann K, Filipits M, Brandstetter A, Weller M, Kurscheid S, Hegi ME, Zielinski CC, Marosi C, Hainfellner JA, Preusser M, Wick W.

Neuro Oncol. 2015 Aug;17(8):1064-75. doi: 10.1093/neuonc/nou307. Epub 2014 Oct 29.

28.

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M; European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium; CENTRIC study team.

Lancet Oncol. 2014 Sep;15(10):1100-8. doi: 10.1016/S1470-2045(14)70379-1. Epub 2014 Aug 19.

29.

Molecular insights into brain tumors: ready for translation into novel treatment strategies?

Hegi ME.

Curr Opin Neurol. 2013 Dec;26(6):678-80. doi: 10.1097/WCO.0000000000000038. No abstract available.

PMID:
24152816
30.

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MP.

J Clin Oncol. 2013 Nov 10;31(32):4085-91. doi: 10.1200/JCO.2013.49.6968. Epub 2013 Oct 7.

31.

Molecular neuro-oncology in clinical practice: a new horizon.

Weller M, Pfister SM, Wick W, Hegi ME, Reifenberger G, Stupp R.

Lancet Oncol. 2013 Aug;14(9):e370-9. doi: 10.1016/S1470-2045(13)70168-2. Review. Erratum in: Lancet Oncol. 2015 May;16(5):e199.

32.

Neuro-oncology: in search of molecular markers of glioma in elderly patients.

Hegi ME, Stupp R.

Nat Rev Neurol. 2013 Aug;9(8):424-5. doi: 10.1038/nrneurol.2013.127. Epub 2013 Jul 2. No abstract available.

PMID:
23817351
33.

Brain cancer in 2012: Molecular characterization leads the way.

Stupp R, Hegi ME.

Nat Rev Clin Oncol. 2013 Feb;10(2):69-70. doi: 10.1038/nrclinonc.2012.240. Epub 2013 Jan 8. Review. No abstract available.

PMID:
23296110
34.

The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.

Johannessen TC, Prestegarden L, Grudic A, Hegi ME, Tysnes BB, Bjerkvig R.

Neuro Oncol. 2013 Mar;15(3):269-78. doi: 10.1093/neuonc/nos301. Epub 2012 Dec 20.

35.

Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.

Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, Sanson M, Wick W, Reifenberger G.

Neuro Oncol. 2012 Sep;14 Suppl 4:iv100-8. doi: 10.1093/neuonc/nos206. Review.

36.

Epidermal growth factor receptor: a re-emerging target in glioblastoma.

Hegi ME, Rajakannu P, Weller M.

Curr Opin Neurol. 2012 Dec;25(6):774-9. doi: 10.1097/WCO.0b013e328359b0bc. Review.

PMID:
23007009
37.

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R; Nordic Clinical Brain Tumour Study Group (NCBTSG).

Lancet Oncol. 2012 Sep;13(9):916-26. Epub 2012 Aug 8.

PMID:
22877848
38.

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.

Bady P, Sciuscio D, Diserens AC, Bloch J, van den Bent MJ, Marosi C, Dietrich PY, Weller M, Mariani L, Heppner FL, Mcdonald DR, Lacombe D, Stupp R, Delorenzi M, Hegi ME.

Acta Neuropathol. 2012 Oct;124(4):547-60. doi: 10.1007/s00401-012-1016-2. Epub 2012 Jul 19. Erratum in: Acta Neuropathol. 2013 Jul;126(1):159.

39.

DNA fingerprinting of glioma cell lines and considerations on similarity measurements.

Bady P, Diserens AC, Castella V, Kalt S, Heinimann K, Hamou MF, Delorenzi M, Hegi ME.

Neuro Oncol. 2012 Jun;14(6):701-11. doi: 10.1093/neuonc/nos072. Epub 2012 May 8.

40.

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).

Nabors LB, Mikkelsen T, Hegi ME, Ye X, Batchelor T, Lesser G, Peereboom D, Rosenfeld MR, Olsen J, Brem S, Fisher JD, Grossman SA; New Approaches to Brain Tumor Therapy (NABTT) Central Nervous System Consortium.

Cancer. 2012 Nov 15;118(22):5601-7. doi: 10.1002/cncr.27585. Epub 2012 Apr 19.

41.

New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials.

Gorlia T, Stupp R, Brandes AA, Rampling RR, Fumoleau P, Dittrich C, Campone MM, Twelves CC, Raymond E, Hegi ME, Lacombe D, van den Bent MJ.

Eur J Cancer. 2012 May;48(8):1176-84. doi: 10.1016/j.ejca.2012.02.004. Epub 2012 Mar 28.

PMID:
22464345
42.

Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.

Hegi ME, Janzer RC, Lambiv WL, Gorlia T, Kouwenhoven MC, Hartmann C, von Deimling A, Martinet D, Besuchet Schmutz N, Diserens AC, Hamou MF, Bady P, Weller M, van den Bent MJ, Mason WP, Mirimanoff RO, Stupp R, Mokhtari K, Wesseling P; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group.

Acta Neuropathol. 2012 Jun;123(6):841-52. doi: 10.1007/s00401-011-0938-4. Epub 2012 Jan 15.

43.

The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence.

Lambiv WL, Vassallo I, Delorenzi M, Shay T, Diserens AC, Misra A, Feuerstein B, Murat A, Migliavacca E, Hamou MF, Sciuscio D, Burger R, Domany E, Stupp R, Hegi ME.

Neuro Oncol. 2011 Jul;13(7):736-47. doi: 10.1093/neuonc/nor036. Epub 2011 Jun 3.

44.

Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.

Hegi ME, Diserens AC, Bady P, Kamoshima Y, Kouwenhoven MC, Delorenzi M, Lambiv WL, Hamou MF, Matter MS, Koch A, Heppner FL, Yonekawa Y, Merlo A, Frei K, Mariani L, Hofer S.

Mol Cancer Ther. 2011 Jun;10(6):1102-12. doi: 10.1158/1535-7163.MCT-11-0048. Epub 2011 Apr 6.

45.

Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres.

Sciuscio D, Diserens AC, van Dommelen K, Martinet D, Jones G, Janzer RC, Pollo C, Hamou MF, Kaina B, Stupp R, Levivier M, Hegi ME.

Clin Cancer Res. 2011 Jan 15;17(2):255-66. doi: 10.1158/1078-0432.CCR-10-1931. Epub 2010 Nov 19.

46.

Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?

Weller M, Wick W, Hegi ME, Stupp R, Tabatabai G.

Future Oncol. 2010 Sep;6(9):1407-14. doi: 10.2217/fon.10.113. Review.

PMID:
20919826
47.

Molecular diagnostics of gliomas: the clinical perspective.

Tabatabai G, Stupp R, van den Bent MJ, Hegi ME, Tonn JC, Wick W, Weller M.

Acta Neuropathol. 2010 Nov;120(5):585-92. doi: 10.1007/s00401-010-0750-6. Epub 2010 Sep 23. Review.

PMID:
20862485
48.

MGMT promoter methylation in malignant gliomas.

Riemenschneider MJ, Hegi ME, Reifenberger G.

Target Oncol. 2010 Sep;5(3):161-5. doi: 10.1007/s11523-010-0153-6. Epub 2010 Aug 20. Review.

PMID:
20725792
49.

Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival.

McDonald KL, McDonnell J, Muntoni A, Henson JD, Hegi ME, von Deimling A, Wheeler HR, Cook RJ, Biggs MT, Little NS, Robinson BG, Reddel RR, Royds JA.

J Neuropathol Exp Neurol. 2010 Jul;69(7):729-36. doi: 10.1097/NEN.0b013e3181e576cf.

PMID:
20535033
50.

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M.

J Clin Oncol. 2010 Jun 1;28(16):2712-8. doi: 10.1200/JCO.2009.26.6650. Epub 2010 May 3.

PMID:
20439646

Supplemental Content

Support Center